The Claim
Rare pathogenic missense variants in the TP53 gene are associated with a substantially reduced lifespan, with carriers exhibiting a hazard ratio of 3.9 for earlier mortality compared to non-carriers, based on analysis of 393,833 individuals of European ancestry from the UK Biobank; these variants disrupt tumor suppression and are strongly linked to increased risk of multiple cancer types, particularly breast and blood cancers.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with rare harmful changes in the TP53 gene tend to live shorter lives, mostly because they’re much more likely to get certain cancers like breast or blood cancer.
See the scientific wording
Rare pathogenic missense variants in the TP53 gene are associated with a substantially reduced lifespan, with carriers showing a hazard ratio of 3.9 for earlier mortality compared to non-carriers, based on analysis of 393,833 individuals of European ancestry in the UK Biobank. These variants are known to disrupt tumor suppression and are strongly linked to multiple cancer types, particularly breast and blood cancers.
What the research says
1 studyStudy: Rare genetic associations with human lifespan in UK Biobank are enriched for oncogenic genes
The study found that harmful rare changes in the TP53 gene are linked to shorter lives, mostly because of cancer, which supports the main idea of the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.